Central Bank & Trust Co. lessened its position in Eli Lilly and Company (NYSE:LLY) by 23.0% in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 1,269 shares of the company’s stock after selling 378 shares during the quarter. Central Bank & Trust Co.’s holdings in Eli Lilly and were worth $104,000 at the end of the most recent reporting period.
Other institutional investors have also recently added to or reduced their stakes in the company. BlackRock Inc. increased its stake in Eli Lilly and by 2,628.5% in the 1st quarter. BlackRock Inc. now owns 62,260,488 shares of the company’s stock worth $5,236,731,000 after buying an additional 59,978,664 shares during the period. Vanguard Group Inc. increased its stake in Eli Lilly and by 3.3% in the 1st quarter. Vanguard Group Inc. now owns 68,597,006 shares of the company’s stock worth $5,769,694,000 after buying an additional 2,181,701 shares during the period. Winslow Capital Management LLC increased its position in Eli Lilly and by 79.7% during the 1st quarter. Winslow Capital Management LLC now owns 3,875,968 shares of the company’s stock valued at $326,008,000 after purchasing an additional 1,719,538 shares during the period. Renaissance Technologies LLC increased its position in Eli Lilly and by 93.6% during the 1st quarter. Renaissance Technologies LLC now owns 2,980,400 shares of the company’s stock valued at $250,681,000 after purchasing an additional 1,441,200 shares during the period. Finally, Alliancebernstein L.P. increased its position in Eli Lilly and by 30.3% during the 1st quarter. Alliancebernstein L.P. now owns 3,477,371 shares of the company’s stock valued at $292,482,000 after purchasing an additional 808,186 shares during the period. Hedge funds and other institutional investors own 75.72% of the company’s stock.
A number of research firms have commented on LLY. Zacks Investment Research raised shares of Eli Lilly and from a “hold” rating to a “buy” rating and set a $94.00 target price on the stock in a research report on Monday, July 17th. Jefferies Group LLC reissued a “buy” rating and set a $93.00 target price on shares of Eli Lilly and in a research report on Thursday, June 22nd. Deutsche Bank AG reissued a “buy” rating and set a $91.00 target price (up previously from $90.00) on shares of Eli Lilly and in a research report on Monday, July 17th. Morgan Stanley reissued a “hold” rating and set a $86.00 target price on shares of Eli Lilly and in a research report on Friday. Finally, Berenberg Bank reissued a “buy” rating and set a $100.00 target price on shares of Eli Lilly and in a research report on Thursday, July 27th. Three research analysts have rated the stock with a sell rating, seven have issued a hold rating and twelve have assigned a buy rating to the stock. The stock currently has a consensus rating of “Hold” and a consensus price target of $88.27.
Shares of Eli Lilly and Company (LLY) traded down 0.93% during midday trading on Tuesday, reaching $81.75. 944,307 shares of the company traded hands. The stock’s 50-day moving average is $80.87 and its 200-day moving average is $82.04. Eli Lilly and Company has a 1-year low of $64.18 and a 1-year high of $86.72. The stock has a market capitalization of $86.25 billion, a P/E ratio of 35.37 and a beta of 0.34.
Eli Lilly and (NYSE:LLY) last released its earnings results on Tuesday, July 25th. The company reported $1.11 EPS for the quarter, beating analysts’ consensus estimates of $1.05 by $0.06. Eli Lilly and had a return on equity of 28.71% and a net margin of 11.12%. The company had revenue of $5.82 billion during the quarter, compared to the consensus estimate of $5.60 billion. During the same quarter last year, the company earned $0.86 earnings per share. Eli Lilly and’s quarterly revenue was up 7.8% compared to the same quarter last year. Equities analysts predict that Eli Lilly and Company will post $4.16 EPS for the current fiscal year.
In other news, major shareholder Lilly Endowment Inc sold 210,000 shares of the firm’s stock in a transaction on Thursday, June 22nd. The stock was sold at an average price of $84.43, for a total value of $17,730,300.00. Following the completion of the transaction, the insider now owns 124,265,804 shares in the company, valued at $10,491,761,831.72. The sale was disclosed in a document filed with the SEC, which is available at this link. In the last 90 days, insiders sold 800,000 shares of company stock valued at $66,281,600. Company insiders own 0.20% of the company’s stock.
About Eli Lilly and
Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company’s human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists.
Receive News & Ratings for Eli Lilly and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and Company and related companies with MarketBeat.com's FREE daily email newsletter.